FDA approves new kind of cholesterol pill

The FDA has approved Lipfendra, a PCSK9 inhibitor cholesterol pill developed by Merck. This new medication is as effective as more expensive injectable drugs but remains more affordable. By lowering LDL cholesterol levels, Lipfendra reduces the risk of heart disease and stroke. This approval provides a cost-effective oral alternative to existing injectable treatments for patients needing to manage their cholesterol levels to prevent serious cardiovascular events and improve overall health outcomes.